Business / Finance

RSS

Salix closes $690 million senior notes offering

Salix Pharmaceuticals, Ltd. today announced the closing of its offering of $690 million aggregate principal amount of 1.5% convertible senior notes due 2019, which includes the exercise in full of the initial purchasers' overallotment option.

17 Mar 2012

Kips Bay Medical fourth quarter net sales decrease to $94,000

Kips Bay Medical, Inc. today announced financial results for fourth quarter and year ended December 31, 2011.

17 Mar 2012

Expanded R&D facility opens at Cubist headquarters

Cubist Pharmaceuticals, Inc. today announced the official opening of its expanded research and development facility at its headquarters at 65 Hayden Avenue in Lexington, Massachusetts.

17 Mar 2012

Baptist Health South Florida named one of 2012 World's Most Ethical Companies

Baptist Health South Florida announced today that Ethisphere Institute has named it as one of the 2012 World's Most Ethical Companies - marking the second straight such honor for Baptist Health.

17 Mar 2012

Echo total revenues increase to $447,000 for fiscal year 2011

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced financial results for the year ended December 31, 2011.

17 Mar 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

PURE Bioscience second quarter revenue increases to $221,000

PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for its second quarter ended January 31, 2012.

17 Mar 2012

ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.

16 Mar 2012

SIPP secures necessary financing commitment from First Fidelity

SIPP International Industries, Inc., the diversified parent company to several divisions in the food, medical, hotel and broadcasting industries, has secured its necessary financing commitment from First Fidelity, Inc. for the manufacturing of the SIPP product lines.

16 Mar 2012

diaDexus fourth quarter total revenues increase 48% to $4.9 million

diaDexus, Inc.a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the 2011 fourth quarter and year-end.

16 Mar 2012

American Shared Hospital Services fourth quarter revenues increase 8.4% to $4,500,000

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the fourth quarter and 2011.

From Elekta 15 Mar 2012

Zynex 2011 net revenue increases 42% to $34,148,000

Zynex, Inc., a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis and cardiac monitoring, announces its 2011 unaudited financial results.

15 Mar 2012

Shire enters agreement to acquire FerroKin BioSciences

Shire plc, the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, regulatory and net sales targets.

15 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

GenVec 2011 net loss decreases to $7.4 million

Today GenVec, Inc. announced financial results for the fourth quarter and year ended December 31, 2011. For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010.

15 Mar 2012